Program Overview
The MDSF ASH 2024 Symposium will focus on challenges the MDS community faces in 2024. Progress has been made in understanding the biology, genetics and pathogenesis of MDS. Prognostication, and treatment strategies have been improved, but not satisfactorily. In 2024 we are still facing problems: Can we assess minimal residual disease? We are still debating regarding the recommended Hb threshold for RBC transfusions. The increasing role of inflammation in the disease pathogenesis, raises the question of anti-inflammatory treatment. The reports on germline mutations and their role in MDS in adulthood might change our genetic screening policy. Finally, we are still puzzled whether patients with higher-risk disease should be treated with hypomethylating agents only, as the only proven treatment, or additional therapy might improve the outcome. The symposium will highlight these challenges, and based on recent advances in the field, potential solutions will be presented and discussed.
Target Audience
This activity is designed for an audience of nurses, pharmacists, physicians, and physician associates.
Learning Objectives
Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS.
More specifically practitioners and researchers:
- Attendees will learn about MRD in MDS
- They will face the question of liberal vs restrictive RBC transfusion policy, and what’s next or in addition to RBC transfusions in LR-MDS
- They will become familiar with the role of inflammation in the pathogenesis of the disease and the potential application of MDS anti-inflammatory treatment.
- The symposium participants will hear about germline mutations and the dilemma of whom of the family members or others should be screened for mutations.
- They will attend the debate whether to continue treating patients with HR-MDS with hypomethylating agents only or should we prefer combination treatments.
- Patient discussion will complete the educational lessons by combining scientific evidence with practical real-life issues. These discussion will focus on patients with LR- and HR-MDS
Speakers
Lionel Ades
Rena Buckstein, MD, FRCPC
Aristoteles Giagounidis, MD
Jaroslaw Maciejewski, MD
Moshe Mittelman, MD
Ghulam J. Mufti, MD
Stephen D. Nimer, MD
Esther Oliva
Casey L. O’Connell, MD
Magnus Tobiasson
Lachelle Weeks
Agenda
07.00 - 07.08 am
Welcome
Stephen Nimer
07.08 - 07.15 am
Challenges in MDS - 2024
Moshe Mittelman
07.15 - 07.35 am
Lecture I: Minimal Residual Disease
Magnus Tobiasson
07.35 - 07.40 am
Q & A
07.40 - 08.05 am
Debate I: The approach for RBC transfusion policy
Liberal: Rena Buckstein; Restrictive: Esther Oliva
08.05 - 08.45 am
Patient Discussion
(Panel: TBA)
08.45 - 09.10 am
Debate II: A role for anti-inflammatory treatment
Yes: Lachelle Weeks; No: Lionel Ades
09.10 - 09.30 am
Lecture II: Who should be screened for germline mutations?
Jaroslaw Maciejewski
09.30 - 09.35 am
Q & A
09.35 - 09.55 am
Debate III: Treatment of HR-MDS (in 2024):
HMA only: Ghulam Mufti; HMA in combination: Aristoteles Giagounidis
09.55 - 10.00 am
Closing Remarks
Casey O’Connell
Register Now
Register now to attend this informative meeting.
Criteria for Success
There is no fee to participate in this activity. Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form available at:
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and MDS. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum
of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses
Credit being awarded: 3 ANCC contact hours
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education
activity for 3 contact hours.
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Disclosures
| Name | Relationship | Commercial Interest |
|---|---|---|
| Lionel Ades | Research Funding & Honoraria | AbbVie, BMS, Novartis, Takeda |
| Rena Buckstein | Advisory Board & Research Consultant | BMS, Taiho, Aaros |
| Aristoteles Giagounidis, MD | Consultant | Amgen, BMS |
| Jaroslaw Maciejewski, MD PhD | Consultant, Speaker, Other | Alexion, Novartis, Omega |
| Moshe Mittelman, MD | Research, Speaker | Roche, Johnson, AbbVie, BMS, Novartis, FibroGen |
| Ghulam Mufti, DM | Research | BMS, Novartis |
| Stephen Nimer | ||
| Casey O’Connell, MD | Advisory Board | Sobi |
| Esther Oliva | Consultant, Royalties, Speaker | BMS, Daiichi Sankyo, Ryvu, Janssen, Amgen, Halia Therapeutics, Alexion, Novartis, Pfizer, Sanofi, Sobi, SYROS |
| Magnus Tobiassen | Honoraria | Pfizer |
| Lachelle Weeks | Consultant | AbbVie, Sobi, Vertex |
| Dorothy Caputo, MA, BSN, RN - VP, Healthcare Continuing Education and Operations | N/A | Nothing to disclose |
| Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer) | N/A | Nothing to disclose |
| Dorothy Duffy, RPh (planner/reviewer) | N/A | Nothing to disclose |
| AKH Inc Staff and Planners | N/A | Nothing to disclose |
| MDS Staff and Planners | N/A | Nothing to disclose |
| All of the relevant financial relationships listed for these individuals have been mitigated. | ||
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
Our Supporters
Thank you to Agios Pharmaceuticals, Inc, Bristol-Myers Squibb, Geron Corporation, Keros Therapeutics, Notable, Rigel Pharmaceuticals, Inc, and Taiho Oncology for supporting this initiative.
